TBI-223

• CAT Number: I037029
• CAS Number: 2071265-08-0
• Molecular Formula: C17H20FN3O5
• Molecular Weight: 365.3614
• Purity: 98%
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: Carbamic acid, N-(((5S)-3-(3-fluoro-4-(2-oxa-6-azaspiro(3.3)hept-6-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, methyl ester
• InChI: InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
• InChIKey: ZNBRXLSWXJKKLJ-LBPRGKRZSA-N
• SMILES: O=C(OC)NC[C@H]1CN(C2=CC=C(N(C3)CC43COC4)C(F)=C2)C(O1)=O

TBI-223 (Cat No.:I037029) is a small molecule inhibitor that targets KRAS G12C, a protein that is commonly mutated in various types of cancer. By inhibiting KRAS G12C, TBI-223 may help slow or halt cancer cell growth. It has shown promise in preclinical studies for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors.

Reference

1: Antibiotics in the clinical pipeline in October 2019 Mark S. Butler, David L. Paterson J Antibiot (Tokyo) 2020; 73(6): 329–364. Published online 2020 Mar 10. doi: 10.1038/s41429-020-0291-8 PMCID: PMC7223789
2: Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy Eveline Torfs, Tatiana Piller, Paul Cos, Davie Cappoen Int J Mol Sci. 2019 Jun; 20(12): 2868. Published online 2019 Jun 12. doi: 10.3390/ijms20122868 PMCID: PMC6627145.